Dr. David serves as Innovation Strategist at the BRI, in addition to being Founder and Managing Director of Pharmagellan, a Boston-area biotech consulting firm.
After studying molecular biophysics and biochemistry at Yale, Dr. David received his M.D. and Ph.D. degrees from Columbia University’s College of Physicians and Surgeons. Dr. David completed his clinical training in anatomic pathology at Brigham and Women’s Hospital, and then served as Instructor in Pathology at Harvard Medical School and Brigham and Women’s, where he researched cell signaling in cancer and kidney development.
As Director in the consulting arm of Leerink Partners, a leading healthcare investment bank, Dr. David led advisory engagements for corporate, commercial, R&D, business development, and investor clients across all major therapeutic areas and business sectors, including biopharma, devices, diagnostics, life sciences tools, and healthcare services. He also co-founded Leerink’s Transactional Consulting practice, which advised financial and strategic investors and early-stage companies side-by-side with Leerink’s investment banking team. Dr. David also served as Director of Strategy in AstraZeneca’s Oncology Innovative Medicines unit, where he led business strategy efforts from target identification through Phase 2a, spearheaded initiatives in end-to-end franchise strategy and portfolio valuation, led external communications focused on R&D collaborators and investors, and provided commercial support to pipeline projects and in-licensing teams.
Dr. David writes about biomedical innovation at Forbes.com and the Pharmagellan blog, and maintains an active presence on Twitter (@Frank_S_David).